{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(4)"],"submitter":["Frantz RP"],"pubmed_abstract":["Macitentan is a dual endothelin receptor antagonist (ERA) approved for treating pulmonary arterial hypertension (PAH). SOPRANO evaluated the efficacy and safety of macitentan versus placebo in pulmonary hypertension (PH) patients after left ventricular assist device (LVAD) implantation. SOPRANO was a phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group study. Patients with an LVAD implanted within the prior 90 days who had persistent PH (i.e., mean pulmonary arterial pressure ≥25 mmHg, pulmonary artery wedge pressure [PAWP] ≤18 mmHg, and pulmonary vascular resistance [PVR] >3 Wood units [WU]) were randomized (1:1) to macitentan 10 mg or placebo once daily for 12 weeks. The primary endpoint was change in PVR. Secondary endpoints included change in right-heart c"],"journal":["Pulmonary circulation"],"pagination":["e12446"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11615754"],"repository":["biostudies-literature"],"pubmed_title":["SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation."],"pmcid":["PMC11615754"],"pubmed_authors":["Franco V","Mandras S","Park MH","Mathier MA","Zhao C","Ewald G","Horn EM","Rame JE","LaRue SJ","Wang IW","Rocco MA","Selej M","Zolty R","Desai SS","Ravichandran AK","Schilling JD","Frantz RP","Rendon GG","Hage A"],"additional_accession":[]},"is_claimable":false,"name":"SOPRANO: Macitentan in patients with pulmonary hypertension following left ventricular assist device implantation.","description":"Macitentan is a dual endothelin receptor antagonist (ERA) approved for treating pulmonary arterial hypertension (PAH). SOPRANO evaluated the efficacy and safety of macitentan versus placebo in pulmonary hypertension (PH) patients after left ventricular assist device (LVAD) implantation. SOPRANO was a phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group study. Patients with an LVAD implanted within the prior 90 days who had persistent PH (i.e., mean pulmonary arterial pressure ≥25 mmHg, pulmonary artery wedge pressure [PAWP] ≤18 mmHg, and pulmonary vascular resistance [PVR] >3 Wood units [WU]) were randomized (1:1) to macitentan 10 mg or placebo once daily for 12 weeks. The primary endpoint was change in PVR. Secondary endpoints included change in right-heart c","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-06-03T00:35:41.927Z","creation":"2025-04-19T14:39:58.92Z"},"accession":"S-EPMC11615754","cross_references":{"pubmed":["39635465"],"doi":["10.1002/pul2.12446"]}}